TCTimothy Campbell

Timothy Campbell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy Campbell has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse Event Reporting in Early-Phase Benign Urology Clinical Trials Using Methods Borrowed From Oncologic Clinical Trials May Inadequately Represent Tolerability

    by Ashley Li, Zijing Cheng, Trevor C. Hunt, Timothy Campbell, Kamil Malshy, Jathin Bandari, Karen M. Doersch

    Purpose: Although most trial design features can be borrowed from oncological trials, benign urology clinical trial design has not been well described. The purpose of this study was to compare serious adverse events (SAEs) and other study characteristics of benign vs malignant lower urinary tract clinical trials to understand safety and tolerability metrics as they apply to clinical trials of benign diseases. Methods: A search was performed on ClinicalTrials.gov for phase 1 benign lower urinary tract and bladder cancer studies from 2000 to 2024. The primary end point was SAE rates. Secondary endpoints were adverse event (AE) rates, all-cause mortality, and AEs requiring therapy termination. Results: A total of 52 clinical trials were included: 18 in the benign group and 34 in the malignant group. The malignant group had significantly higher number of SAEs and AEs. At the subject-level analysis, 284/987 subjects (28.77%) in the malignant group experienced a SAE compared with 16/554 subjects (2.89%) in the benign group (P < .001). AEs occurred in 818 subjects (82.88%) in the malignant trials and 222 subjects (40.07%) in the benign trials (P < .001). Despite these dissimilarities, there was no significant difference in the rate of AEs requiring therapy termination. Conclusions: There are significantly higher rates of SAE, AE, and mortality in malignant bladder phase 1 trials, but no difference in therapy termination in comparison with benign trials. More specifics in AE severity, reasons for therapy discontinuation, and study dropout need to be reported to guide future benign urology clinical trials.


  • Low-dose fluoroscopy technique drastically decreases patient radiation exposure during percutaneous nephrolithotomy

    by Galen Cheng, Timothy Campbell, Changyong Feng, Scott Quarrier, Rajat Jain

    Fluoroscopy is essential in percutaneous nephrolithotomy (PCNL) but exposes patients and operating room staff to radiation. We investigated whether a low-dose (LD) protocol could reduce radiation exposure during fluoroscopy-guided access without compromising clinical outcomes. Patients undergoing PCNL with fluoroscopy-guided access at a tertiary care stone center between January 2019 and July 2021 were identified. Prior to September 3, 2020, the Philips Veradius C-arm’s default settings were used: standard per-frame dose, 15 pulses per second (PPS) frame rate. After this date, a low-dose protocol was used: reduced per-frame dose, reduced frame rate of 8 PPS for needle puncture and 4 PPS for all other steps. Clinical and radiographical data were retrospectively collected. The primary outcome was cumulative radiation dose. Secondary outcomes were stone-free status (SFS; defined as no fragments ≥ 2 mm) and complications. Multivariate regression analysis was performed. 100 patients were identified; 31 were in the LD group. The LD cohort was exposed to a significantly lower mean cumulative radiation dose of 11.68 mGy compared to 48.88 mGy (p < 0.0001). There were no differences in operative time, fluoroscopy time, stone burden, SFS, or complications. In a multivariable regression model adjusting for several variables, LD protocol was associated with lower radiation dose while skin-to-calyx-distance (STCD) was positively associated with cumulative radiation dose. Low-dose fluoroscopy and decreased frame rate during PCNL decreased radiation exposure fourfold without affecting SFS or complication rates.